Literature DB >> 21308518

Adjunct therapy for sepsis: how early?

Djillali Annane1.   

Abstract

Sepsis is a leading cause of death worldwide. The management of patients is primarily based on curing the infectious process with anti-infective drugs and/or surgical drainage. Simultaneously, treatment includes optimization of oxygen use by tissues via appropriate oxygen therapy and respiratory and hemodynamic management. At best, initiating appropriate anti-infective and symptomatic treatments should lead to patient improvement within a few hours. Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis. These treatments should optimally be started within 24 hours of the onset of shock. They should be initiated in those patients who did not adequately respond after 6 hours of optimal anti-infective and symptomatic treatments.

Entities:  

Year:  2010        PMID: 21308518     DOI: 10.1007/s11908-010-0123-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  38 in total

Review 1.  Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance.

Authors:  S Schmidt; J Rainer; C Ploner; E Presul; S Riml; R Kofler
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

Review 2.  Activated protein C for sepsis.

Authors:  Susanne Toussaint; Herwig Gerlach
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

Review 3.  Corticosteroids: way upstream.

Authors:  Therese Riedemann; Alexandre V Patchev; Kwangwook Cho; Osborne F X Almeida
Journal:  Mol Brain       Date:  2010-01-11       Impact factor: 4.041

4.  Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation.

Authors:  G M Patrassi; M T Sartori; U Livi; A Casonato; C Danesin; S Vettore; A Girolami
Journal:  Transplantation       Date:  1997-12-15       Impact factor: 4.939

5.  Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1.

Authors:  Eszter Dömötör; Omar Benzakour; John H Griffin; David Yule; Kenji Fukudome; Berislav V Zlokovic
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

Review 6.  Septic shock.

Authors:  Djillali Annane; Eric Bellissant; Jean-Marc Cavaillon
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

7.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Authors:  Marcel Levi; Mitchell Levy; Mark D Williams; Ivor Douglas; Antonio Artigas; Massimo Antonelli; Duncan Wyncoll; Jonathan Janes; Frank V Booth; Dazhe Wang; David P Sundin; William L Macias
Journal:  Am J Respir Crit Care Med       Date:  2007-06-07       Impact factor: 21.405

8.  Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation.

Authors:  J J van Giezen; J W Jansen
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

9.  Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.

Authors:  G Umberto Meduri; Emmel Golden; Amado X Freire; Edwin Taylor; Muhammad Zaman; Stephanie J Carson; Mary Gibson; Reba Umberger
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

10.  Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.

Authors:  Djillali Annane; Alain Cariou; Virginie Maxime; Elie Azoulay; Gilles D'honneur; Jean François Timsit; Yves Cohen; Michel Wolf; Muriel Fartoukh; Christophe Adrie; Charles Santré; Pierre Edouard Bollaert; Armelle Mathonet; Roland Amathieu; Alexis Tabah; Christophe Clec'h; Julien Mayaux; Julie Lejeune; Sylvie Chevret
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

View more
  1 in total

1.  Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial.

Authors:  Djillali Annane; Christian Brun Buisson; Alain Cariou; Claude Martin; Benoit Misset; Alain Renault; Blandine Lehmann; Valérie Millul; Virginie Maxime; Eric Bellissant
Journal:  Ann Intensive Care       Date:  2016-05-06       Impact factor: 6.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.